Connor, Clark & Lunn Investment Management (CC&L)
ACHN

Connor, Clark & Lunn Investment Management (CC&L)’s Achillion Pharmaceuticals ACHN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-68,034
Closed -$182K – 1149
2019
Q2 		$182K Sell
68,034
-40,695
-37% -$120K ﹤0.01% 912
2019
Q1 		$322K Sell
108,729
-47,125
-30% -$116K ﹤0.01% 735
2018
Q4 		$248K Buy
155,854
+33,097
+27% +$93.6K ﹤0.01% 817
2018
Q3 		$452K Buy
122,757
+20,450
+20% +$60.9K ﹤0.01% 718
2018
Q2 		$290K Buy
102,307
+3,115
+3% +$10.6K ﹤0.01% 887
2018
Q1 		$368K Buy
99,192
+2,700
+3% +$8.84K ﹤0.01% 604
2017
Q4 		$278K Sell
96,492
-83,982
-47% -$305K ﹤0.01% 691
2017
Q3 		$810K Sell
180,474
-162,075
-47% -$720K ﹤0.01% 563
2017
Q2 		$1.57M Buy
342,549
+32,300
+10% +$130K 0.01% 426
2017
Q1 		$1.31M Sell
310,249
-50,600
-14% -$210K 0.01% 457
2016
Q4 		$1.49M Sell
360,849
-206,658
-36% -$1.1M 0.01% 416
2016
Q3 		$4.6M Sell
567,507
-276,440
-33% -$2.35M 0.03% 258
2016
Q2 		$6.58M Sell
843,947
-242,500
-22% -$2.08M 0.05% 211
2016
Q1 		$8.39M Sell
1,086,447
-184,600
-15% -$1.35M 0.07% 174
2015
Q4 		$13.7M Buy
1,271,047
+306,900
+32% +$2.79M 0.11% 112
2015
Q3 		$6.66M Buy
964,147
+458,725
+91% +$3.74M 0.05% 169
2015
Q2 		$4.48M Buy
505,422
+88,150
+21% +$834K 0.04% 165
2015
Q1 		$4.11M Buy
417,272
+158,100
+61% +$1.97M 0.03% 173
2014
Q4 		$3.17M Buy
259,172
+185,072
+250% +$2.26M 0.03% 185
2014
Q3 		$740K Buy
74,100
+500
+0.7% +$4.64K 0.01% 343
2014
Q2 		$593K Buy
+73,600
New +$294K ﹤0.01% 373

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ACHN Position: Q3 2019 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Achillion Pharmaceuticals (ACHN) in Q3 2019, closing a stake of 68,034 shares — an estimated $182K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ACHN in Q2 2014 and held it in 21 quarters. The position peaked at $13.7M in Q4 2015. 122 funds tracked by Wall St. Rank hold ACHN as of Q3 2019.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Achillion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 68,034 Achillion Pharmaceuticals shares in Q3 2019, an estimated $182K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 21 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Achillion Pharmaceuticals position peaked at $13.7M in Q4 2015.
  • 122 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2019.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2019, filed 13 Nov 2019.